Compare SAH & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAH | NTLA |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 986.9M |
| IPO Year | 1997 | 2016 |
| Metric | SAH | NTLA |
|---|---|---|
| Price | $63.49 | $9.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 22 |
| Target Price | ★ $80.75 | $19.83 |
| AVG Volume (30 Days) | 203.7K | ★ 4.0M |
| Earning Date | 10-23-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.73 | N/A |
| Revenue | ★ $15,178,100,000.00 | $57,528,000.00 |
| Revenue This Year | $7.85 | $1.96 |
| Revenue Next Year | $3.49 | N/A |
| P/E Ratio | $17.01 | ★ N/A |
| Revenue Growth | 9.09 | ★ 33.52 |
| 52 Week Low | $52.00 | $5.90 |
| 52 Week High | $89.62 | $28.25 |
| Indicator | SAH | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 44.38 | 45.58 |
| Support Level | $64.51 | $8.74 |
| Resistance Level | $65.79 | $9.55 |
| Average True Range (ATR) | 2.00 | 0.56 |
| MACD | 0.08 | 0.30 |
| Stochastic Oscillator | 22.50 | 73.99 |
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 108 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores, 16 collision centers, and 14 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 59% of new-vehicle revenue. BMW is the largest brand at about 25%. 2024's revenue was $14.2 billion, with Texas and California comprising 51% of the total. EchoPark's portion was $2.1 billion.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.